Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry

UroGen Pharma files patent infringement action against Teva Pharmaceuticals

Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities

These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets

Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India

Executes the first project for developing and manufacturing a novel anticancer mAb

lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary

Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment

WuXi Biologics breaks ground on CRDMO Center in Singapore

The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network